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Cell-to-cell communicationAbstract Exosomes are 40–100 nm nano-sized vesicles that are released from many cell types into
the extracellular space. Such vesicles are widely distributed in various body ﬂuids. Recently,
mRNAs and microRNAs (miRNAs) have been identiﬁed in exosomes, which can be taken up by
neighboring or distant cells and subsequently modulate recipient cells. This suggests an active sort-
ing mechanism of exosomal miRNAs, since the miRNA proﬁles of exosomes may differ from those
of the parent cells. Exosomal miRNAs play an important role in disease progression, and can stimu-
late angiogenesis and facilitate metastasis in cancers. In this review, we will introduce the origin and
the trafﬁcking of exosomes between cells, display current research on the sorting mechanism of exo-
somal miRNAs, and brieﬂy describe how exosomes and their miRNAs function in recipient cells.
Finally, we will discuss the potential applications of these miRNA-containing vesicles in clinical
settings.Introduction
Exosomes, membrane-bound vesicles of 40–100 nm in diame-
ter, are present in almost all biological ﬂuids [1–3]. They are
released from most cell types into the extracellular space after
fusion with the plasma membrane [1–3]. Lipids and proteins
are the main components of exosome membranes, which are
enriched with lipid rafts [1–3]. In addition to the proteins, vari-
ous nucleic acids have recently been identiﬁed in the exosomalnces and
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non-coding RNAs (ncRNAs) [4]. These exosomal RNAs can
be taken up by neighboring cells or distant cells when exo-
somes circulate, and they subsequently modulate recipient
cells. The discovery of their function in genetic exchange
between cells has brought increasing attention to exosomes.
MicroRNAs are a class of 17–24 nt small, noncoding
RNAs, which mediate post-transcriptional gene silencing by
binding to the 30-untranslated region (UTR) or open reading
frame (ORF) region of target mRNAs [5]. The involvement
of miRNAs in many biological activities has been well docu-
mented, including cell proliferation, cell differentiation, cell
migration, disease initiation, and disease progression [6–10].
Accumulating evidence has shown that miRNAs can stably
exist in body ﬂuids, including saliva [11,12], urine [13], breast
milk [14], and blood [11,15,16]. In addition to being packed
into exosomes or microvesicles, extracellular miRNAs can be
loaded into high-density lipoprotein (HDL) [17,18], or bound
by AGO2 protein outside of vesicles [16]. All these three modes
of action protect miRNAs from degradation and guarantee
their stability. Given the transportability of vesicles, the role
of miRNAs in exosomes is gaining increasing attention.
Conveying information via circulating vesicles is deemed to
be the third way of intercellular communication that is as
essential as the cell-to-cell contact-dependent signaling and sig-
naling via transfer of soluble molecules [19,20].
Formation and secretion of exosomes require enzymes
[21,22] and ATP [23], and the miRNA and mRNA proﬁles
of exosomes differ from those of the parent cells [24].
Therefore, cells may possess an active selecting mechanism
for exosomes and their cargos. Besides, functions of the trans-
ferred exosomal molecular constituents in the recipient cells
are under investigation. Hereby, this review will concisely
introduce the origin and trafﬁcking of exosomes and discuss
the sorting mechanism and function of exosomal miRNAs.
Formation and secretion of exosomes
Exosomes were ﬁrst discovered by Pan and Johnstone in 1983
[25]. They reported that the release of transferrin receptors into
the extracellular space during the maturation of sheep retic-
ulocytes was associated with a type of small vesicle [23,25].
In 1989, Johnstone deﬁned such functional vesicles as exo-
somes [26]. To date, a series of extracellular vesicles have been
described [27]. However, in the last three decades, no uniﬁed
terminology for extracellular vesicles has been presented. The
deﬁnition for such extracellular vesicles named as microvesi-
cles, exosomes, and microparticles remains confusing among
different reports [28–30]. Now, according to the way of vesicu-
lar secretion from cells, extracellular vesicles can be grouped
into two general classes. One of these classes is known as
microvesicles, which are directly shed from the cell membrane.
The other is known as exosomes, which are released by exo-
cytosis when multivesicular bodies (MVBs) fuse with the
plasma membrane [31]. Here, we mainly focus on the second
group of vesicles, i.e., exosomes.
Exosomes can be revealed using transmission microscopy,
possessing a cup-shaped morphology after negative staining
[1–3]. These vesicles can be concentrated in the 1.10–1.21
g/ml section of a sucrose density gradient [1–3]. They can
also be identiﬁed by the presence of proteins common to mostexosomes, such as the tetraspanin proteins CD63, CD9, and
CD81 [1–3].
As mentioned above, exosomes are originally formed by
endocytosis. First, the cell membrane is internalized to produce
endosomes. Subsequently, many small vesicles are formed
inside the endosome by invaginating parts of the endosome
membranes. Such endosomes are called MVBs. Finally, the
MVBs fuse with the cell membrane and release the intralumi-
nal endosomal vesicles into the extracellular space to become
exosomes [32].
The regulatory molecules involved in the release of exo-
somes were identiﬁed by Ostrowski and colleagues, who
observed that Rab27a and Rab27b were associated with exo-
some secretion. Knockdown of Rab27 or their effectors,
SYTL4 and EXPH5, could inhibit secretion of exosomes in
HeLa cells [33]. Moreover, Yu et al. discovered that both the
tumor repressor protein p53 and its downstream effector
TSAP6 could enhance exosome production [34]. Baietti et al.
found that syndecan-syntenin interacted directly with ALIX
protein via Leu-Tyr-Pro-X(n)-Leu motif to support the
intraluminal budding of endosomal membranes, which is an
important step in exosome formation [35]. All of these studies
indicate that a set of molecules act as a regulatory network and
are responsible for the formation and secretion of exosomes in
parent cells.
The trafﬁcking of exosomes
Exosomes present in body ﬂuids play an important role in
exchanging information between cells. In general, there are
three mechanisms of interaction between exosomes and their
recipient cells. First, the transmembrane proteins of exosomes
directly interact with the signaling receptors of target cells [36].
Second, the exosomes fuse with the plasma membrane of
recipient cells and deliver their content into the cytosol [37].
Third, the exosomes are internalized into the recipient cells
and have two fates. In one case, some engulfed exosomes
may merge into endosomes and undergo transcytosis, which
will move exosomes across the recipient cells and release them
into neighboring cells. In the other case, endosomes fused from
engulfed exosomes will mature into lysosomes and undergo
degradation [37,38]. Some recent studies have reported the fac-
tors inﬂuencing internalization of exosomes in recipient cells.
Koumangoye et al. observed that disruption of exosomal lipid
rafts resulted in the inhibition of internalization of exosomes
and that annexins, which are related to cell adhesion and
growth, were essential for the uptake of exosomes in the breast
carcinoma cell line BT-549 [39]. Escrevente et al. described a
decrease in exosome uptake after the ovarian carcinoma cell
line SKOV3 and its derived exosomes were treated with pro-
tease K, which indicated that the proteins mediating exosome
internalization are presented on the surface of both the cells
and the exosomes [40]. However, the detailed mechanism of
exosome internalization is still not well understood.The function of exosomes
Exosomes can be released from many cell types, such as blood
cells, endothelial cells, immunocytes, platelets, and smooth
muscle cells [41–43]. It is believed that exosomes can regulate
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lipids, proteins, and nucleic acids while circulating in the extra-
cellular space. Several reports have shown that exosomes play
important roles in immune response, tumor progression, and
neurodegenerative disorders. Esther et al. reported that acti-
vated T cells could recruit dendritic cell (DC)-derived exo-
somes that contain major histocompatibility complex (MHC)
class II to down-regulate the immune response during interac-
tion of T cells and DCs [44]. Exosomes derived from platelets
that were treated with thrombin and collagen stimulated pro-
liferation and increased chemoinvasion in the lung adenocarci-
noma cell line A549 [45]. Exosomes derived from SGC7901
promoted the proliferation of SGC7901 and another gastric
cancer cell line, BGC823 [46]. In addition, CD147-positive exo-
somes derived from epithelial ovarian cancer cells promoted
angiogenesis in endothelial cells in vitro [47]. Interestingly,
Webber et al. incubated exosomes derived from a mesothe-
lioma cell line, a prostate cancer cell line, a bladder cancer cell
line, a colorectal cancer cell line, and a breast cancer cell line
with primary ﬁbroblasts in vitro, and found that ﬁbroblasts
could be transformed into myoﬁbroblasts [48]. A similar phe-
nomenon was also observed by Cho et al., who described that
tumor-derived exosomes converted mesenchymal stem cells
within the stroma of the tumor tissue into cancer-associated
myoﬁbroblasts [49]. Although the function of exosomes has
been documented in the aforementioned studies, it remains
an open question which speciﬁc class of molecules contained
in exosomes inﬂuences the recipient cells.The sorting mechanism for exosomal miRNAs
As described above, a wide variety of molecules are contained
in exosomes, including proteins, lipids, DNAs, mRNAs, and
miRNAs, which are recorded in the ExoCarta database [50].
Among these molecules, miRNAs have attracted most atten-
tion, due to their regulatory roles in gene expression. Goldie
et al. demonstrated that, among small RNAs, the proportion
of miRNA is higher in exosomes than in their parent cells
[51]. As some proﬁling studies have shown, miRNAs are not
randomly incorporated into exosomes. Guduric-Fuchs et al.
analyzed miRNA expression levels in a variety of cell lines
and their respective derived exosomes, and found that a subset
of miRNAs (e.g., miR-150, miR-142-3p, and miR-451)
preferentially enter exosomes [52]. Similarly, Ohshima et al.
compared the expression levels of let-7 miRNA family mem-
bers in exosomes derived from the gastric cancer cell line
AZ-P7a with those from other cancer cell lines, including the
lung cancer cell line SBC-3/DMS-35/NCI-H69, the colorectal
cancer cell line SW480/SW620, and the stomach cancer cell
line AZ-521. As a result, they found that members of the let-
7 miRNA family are abundant in exosomes derived from
AZ-P7a, but are less abundant in exosomes derived from other
cancer cells [53]. Moreover, some reports have shown that exo-
somal miRNA expression levels are altered under different
physiological conditions. The level of miR-21 was lower in
exosomes from the serum of healthy donors than those
glioblastoma patients [29]. Levels of let-7f, miR-20b, and
miR-30e-3p were lower in vesicles from the plasma of non-
small-cell lung carcinoma patients than normal controls [30].
Different levels of eight exosomal miRNAs, including miR-
21 and miR141, were also found between benign tumors andovarian cancers [54]. All these studies show that parent cells
possess a sorting mechanism that guides speciﬁc intracellular
miRNAs to enter exosomes.
According to previous studies, there exists a class of
miRNAs that are preferentially sorted into exosomes, such
as miR-320 and miR-150. Members of the miR-320 family
are widely distributed in exosomes derived from normal tissue
and tumors [29,41,52,55,56]. miR-150 is highly expressed in
exosomes derived from the HEK293T cell line, peripheral
blood of tumor patients, colony-stimulating factor 1 (CSF-
1)-induced bone marrow-derived macrophages, and the serum
of colon cancer patients [52,54,55,57,58]. In addition, some
miRNAs, miR-451 for example, are highly expressed in exo-
somes derived from normal cells, such as the HMC-1 cell line,
the HEK293T cell line, primary T lymphocytes, and Epstein–
Barr virus-transformed lymphoblastoid B-cells [52,59–61].
Other miRNAs, such as miR-214 and miR-155, are enriched
in exosomes derived from tumor cell lines or peripheral blood
from cancer patients [54,58,62].
Based on current research, there are four potential modes
for sorting of miRNAs into exosomes, although the underlying
mechanisms remain largely unclear. These include: 1) The neu-
ral sphingomyelinase 2 (nSMase2)-dependent pathway.
nSMase2 is the ﬁrst molecule reported to be related to
miRNA secretion into exosomes. Kosaka et al. found that
overexpression of nSMase2 increased the number of exosomal
miRNAs, and conversely inhibition of nSMase2 expression
reduced the number of exosomal miRNAs [22]. 2) The
miRNA motif and sumoylated heterogeneous nuclear ribonu-
cleoproteins (hnRNPs)-dependent pathway. Villarroya-Beltri
et al. discovered that sumoylated hnRNPA2B1 could recog-
nize the GGAG motif in the 30 portion of miRNA sequences
and cause speciﬁc miRNAs to be packed into exosomes [59].
Similarly, another two hnRNP family proteins, hnRNPA1
and hnRNPC, can also bind to exosomal miRNAs, suggesting
that they might be candidates for miRNA sorting as well.
However, no binding motifs have been identiﬁed yet [59]. 3)
The 30-end of the miRNA sequence-dependent pathway.
Koppers-Lalic et al. discovered that the 30 ends of uridylated
endogenous miRNAs were mainly presented in exosomes
derived from B cells or urine, whereas the 30 ends of adenylated
endogenous miRNAs were mainly presented in B cells [60].
The above two selection modes commonly indicate that the
30 portion or the 30 end of the miRNA sequence contains a
critical sorting signal. 4) The miRNA induced silencing com-
plex (miRISC)-related pathway. It is well known that mature
miRNAs can interact with assembly proteins to form a com-
plex called miRISC. The main components of miRISC include
miRNA, miRNA-repressible mRNA, GW182, and AGO2.
The AGO2 protein in humans, which prefers to bind to U or
A at the 50 end of miRNAs, plays an important role in mediat-
ing mRNA:miRNA formation and the consequent transla-
tional repression or degradation of the mRNA molecule [63].
Recent studies recognized a possible correlation between
AGO2 and exosomal miRNA sorting. In exosomal protein
analyses, AGO2 has sometimes been identiﬁed by using mass
spectrometry (MS) or Western blotting [51,64]. Guduric-
Fuchs et al. discovered that knockout of AGO2 could decrease
the types or abundance of the preferentially-exported
miRNAs, such as miR-451, miR-150, and miR-142-3p, in
HEK293T-derived exosomes [52]. Other evidence has also sup-
ported a relationship between miRISC and exosomal miRNA
20 Genomics Proteomics Bioinformatics 13 (2015) 17–24sorting. First, the main components of miRISC were found to
be co-localized with MVBs [65]. Second, blockage of the turn-
over of MVBs into lysosomes could lead to the over-accumu-
lation of miRISCs, whereas blockage of the formation of
MVBs resulted in the loss of miRISCs [66]. Third, the changes
in miRNA-repressible targets levels that occur in response to
cell activation may cause miRNA sorting to exosomes, par-
tially by differentially engaging them at the sites of miRNA
activity (miRISCs) and exosome biogenesis (MVBs) [55]. In
summary, speciﬁc sequences present in certain miRNAs may
guide their incorporation into exosomes, whereas some
enzymes or other proteins may control sorting of exosomal
miRNAs as well, in a miRNA sequence-independent fashion
(Figure 1).The function of exosomal miRNAs
Since Valadi et al. [24] described that miRNAs could be trans-
ferred between cells via exosomes, more similar observationsAAA
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Figure 1 The sorting mechanism for exosomal microRNAs
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acceptor cells, exosomal miRNAs play functional roles.
Although it is difﬁcult to completely exclude the effects of
other exosomal cargos on recipient cells, miRNAs are consid-
ered the key functional elements. The functions of exosomal
miRNAs can be generally classiﬁed into two types. One is
the conventional function, i.e., miRNAs perform negative reg-
ulation and confer characteristic changes in the expression
levels of target genes. For example, exosomal miR-105 released
from the breast cancer cell lines MCF-10A and MDA-MB-231
reduced ZO-1 gene expression in endothelial cells and pro-
moted metastases to the lung and brain [70]. Exosomal miR-
214, derived from the human microvascular endothelial cell
line HMEC-1, stimulated migration and angiogenesis in neigh-
boring HMEC-1 cells [71]. Exosomal miR-92a, derived from
K562 cells, signiﬁcantly reduced the expression of integrin a5
in the human umbilical vein endothelial (HUVEC) cells and
enhanced endothelial cell migration and tube formation [72].A
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some miRNAs when they are studied as exosomal miRNAs
rather than intracellular miRNAs. Exosomal miR-21 and
miR-29a, in addition to the classic role of targeting mRNA,
were ﬁrst discovered to have the capacity to act as ligands that
bind to toll-like receptors (TLRs) and activate immune cells
[73]. This study uncovered an entirely new function of
miRNAs. To further understand this novel function of
miRNAs, more investigations are worthwhile.
Notably, current functional studies of exosomal miRNAs
have some limitations. First, diverse methods are used for exo-
some isolation. Exosomes can be enriched from cell culture
media by ultracentrifugation, density gradient separation,
immunoafﬁnity capture, size exclusion chromatography, and
ExoQuick Precipitation (System Biosciences, USA). Use of
different exosome puriﬁcation strategies could slightly affect
exosomal contents, including proteins and miRNAs [74–76].
Second, the large number of variable miRNAs carried by exo-
somes may regulate many different signaling pathways, and
will generate integral effects on recipient cells. Therefore, it is
difﬁcult to gain a thorough understanding of the functions
of exosomal miRNAs. According to studies of miRNA sorting
mechanisms, certain miRNAs may be classiﬁed by portions of
their sequences, and the functions of each group may be eluci-
dated separately. Third, it is difﬁcult to identify exosomal
miRNAs in a single exosome or to measure the amount of a
given miRNA carried by an exosome when it is present in
low abundance. Chevillet et al. quantiﬁed the number of exo-
somes by a NanoSight instrument (Malvern, UK) and theTable 1 Exosomal microRNAs capable of distinguishing different path
Sample description Isolation strategy
Tumor cells from glioblastoma
patients at passage 1–15; serum from
glioblastoma patients and controls
Ultracentrifugation
Plasma from NSCLC patients
(n= 28 for test, n= 78 for
validation); plasma from controls
(n= 20 for test, n= 48 for
validation)
Immunobead (EpCAM)
Serum from malignant tumor
patients (n= 50); serum from benign
tumor patients (n= 10); serum from
controls (n= 10).
Immunobead (EpCAM) and
ultracentrifugation
Plasma from lung adenocarcinoma
(n= 27); plasma from control
(n= 9).
Size exclusion chromatography and
immunobead (EpCAM)
Note: NSCLC, non-small-cell lung carcinoma; EpCAM, epithelial cell adhnumber of miRNA molecules in an exosome collection using
a real-time PCR-based absolute quantiﬁcation method. They
found that, on average, most exosomes did not harbor many
copies of miRNA molecule [77]. According to this study, accu-
mulation of exosomal miRNAs in recipient cells is necessary
for miRNA-based communication. More sophisticated tech-
niques and methods need to be developed to enrich the sub-
population of miRNA-rich exosomes, and functionally
sufﬁcient quantities of exosomal miRNAs need to be
determined.Applications of exosomes and exosomal miRNAs
Exosomal miRNAs can stably exist in the blood, urine, and
other body ﬂuids of patients, and exosomes can reﬂect their tis-
sue or cell of origin by the presence of speciﬁc surface proteins
[1–3]. Furthermore, the amount and composition of exosomal
miRNAs differ between patients with disease and healthy
individuals. Thus, exosomal miRNAs show potential for use
as noninvasive biomarkers to indicate disease states. Several
previous studies have proﬁled exosomal miRNAs in different
samples. It is of note that some exosomal miRNAs can be used
to aid in clinical diagnosis (Table 1) [29,30,54,62]. For exam-
ple, a set of exosomal miRNAs, including let-7a, miR-1229,
miR-1246, miR-150, miR-21, miR-223, and miR-23a, can be
used as the diagnostic biomarker of colorectal cancer [57].
Another set, miR-1290 and miR-375, can be used as the prog-
nostic marker in castration-resistant prostate cancer [56].ological conditions in patients
Quantiﬁcation method Findings Ref.
Quantitative PCR 11 miRNAs (miR-15b, miR-16, miR-
196, miR-21, miR-26a, miR-27a,
miR-92, miR-93, miR-320, miR-20,
and let-7a) were known to be
abundant in gliomas, able to be
detected in their derived
microvesicles; the level of exosomal
miR-21 was elevated in serum
microvesicles compared with controls
[29]
Quantitative PCR The levels of exosomal let-7f and/or
miR-30e-3p in NSCLC patients can
distinguish patients with resectable
tumors from those with non-
resectable tumors
[30]
Microarray The levels of 8 exosomal miRNAs
(miR-21, miR141, miR-200a, miR-
200b, miR-200c, miR-203, miR-205,
and miR-214) from malignant tumor
are signiﬁcantly distinct from those
observed in benign tumor; exosomal
miRNAs could not be detected in
normal controls
[54]
Microarray The levels of 12 exosomal miRNAs
(miR-17-3p, miR-21, miR-106a, miR-
146, miR155, miR-191, miR-192,
miR-203, miR-205, miR-210, miR-
212, and miR-214) are signiﬁcantly
diﬀerent between patients and
controls
[62]
esion molecule.
22 Genomics Proteomics Bioinformatics 13 (2015) 17–24Besides the endogenous miRNAs, exogenous miRNAs can
also be sorted into exosomes, which has been experimentally
conﬁrmed by Pegtel et al. [78] and Meckes et al. [79], who
observed that human tumor viruses can exploit exosomes as
delivery vectors to transfer their exogenous miRNAs to other
non-infected cells [78,79]. Hence, exogenous small RNAs have
also been transferred by exosomes by mimicking the molecular
mechanism of endogenous miRNAs transportation.
RNA interference (RNAi) has been applied to gene therapy
[80,81]. The ﬁndings on the employment of exosomes by the
exogenous miRNAs suggest that combination of exosomes
with RNAi technology is a promising method for gene therapy
and this idea has been supported by several lines of evidence.
For instance, Wahlgren et al. used plasma exosomes as gene
delivery platforms to transfer exogenous siRNAs to monocytes
and lymphocytes, which resulted in the silencing of the target
MAPK gene [82]. In addition, Shtam et al. introduced exoge-
nous siRNA into exosomes derived from HeLa cells, and used
these transfected exosomes to knock down the target gene
RAD51 in the recipient cells [83]. Moreover, the effect of exo-
some-siRNA gene silencing has also been validated in a mouse
model [84]. It is therefore possible to use exosomes to modulate
target genes for therapeutic purposes, but a great deal of addi-
tional research will be required to develop these therapies for
clinical use.
Perspective
Although exosomes were ﬁrst identiﬁed in the 1980s, studies
on exosomes have been increasing remarkably during the last
ﬁve years, especially following the discovery of functional
mRNAs and miRNAs in exosomes. Exosomes play a key role
in the process of cell-to-cell communication and inﬂuence the
phenotype of recipient cells. However, exosome study is still
in its infancy. People may want to know whether other non-
coding RNAs such as long non coding RNAs could be present
in exosomes, and whether they get involved in target gene reg-
ulation in recipient cells. With the discovery that exosomal
miRNAs can function as ligands, a new ﬁeld in exosome study
has been opened up. It remains controversial whether the
mechanism for packing of bioactive molecules into exosomes
and secreting them into the extracellular space is an active or
a passive process. More investigations on this matter will be
warranted. Nonetheless, the most exciting but challenging
application will be to utilize exosomes and their cargo as a
clinical tool to diagnose and monitor disease, perhaps even
for gene therapy, but much work remains to achieve this goal.
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